Prognostic significance of the postoperative level and recovery rate of serum albumin in patients with curatively resected pancreatic ductal adenocarcinoma

Yutaka Nakano, Minoru Kitago, Masahiro Shinoda, Hiroshi Yagi, Yuta Abe, Kiminori Takano, Go Oshima, Ayano Takeuch, Yutaka Endo, Yuko Kitagawa

Research output: Contribution to journalArticle

Abstract

The aim of the present study was to investigate the clinicopathological features and prognostic factors associated with pre- and postoperative serum albumin levels in patients with curatively resected pancreatic ductal adenocarcinoma (PDAC). To achieve this, the data of patients who underwent pancreatectomy for PDAC between January 1995 and March 2016 were retrospectively reviewed, and the pre- and postoperative serum albumin levels at postoperative months (POMs) 3, 6, and 12 were evaluated. The serum albumin recovery rate was also investigated. A total of 196 patients were enrolled in the present study. In the multivariate Cox regression analysis, lymph node metastasis [hazard ratio (HR): 1.65; P=0.022], serum albumin level at POM 12 (≥3.9 g/dl; HR: 0.60; P=0.017), and serum albumin recovery rate at POM 12 (≥1.00; HR: 0.60; P=0.017) were independent prognostic factors for disease-free survival. Lymph node metastasis (HR: 1.79; P=0.013) and serum albumin level at POM 12 (≥3.9 g/dl) (HR: 0.60; P=0.033) were independent prognostic factors for overall survival. These results indicated that the postoperative level and recovery rate of serum albumin are potential biomarkers for predicting the prognosis of patients with curatively resected PDAC. However, further studies are required in order to investigate the survival benefit of increasing postoperative serum albumin levels in these patients.

Original languageEnglish
Pages (from-to)270-278
Number of pages9
JournalMolecular and Clinical Oncology
Volume11
Issue number3
DOIs
Publication statusPublished - 2019 Sep 1

Fingerprint

Serum Albumin
Adenocarcinoma
Lymph Nodes
Neoplasm Metastasis
Pancreatectomy
Survival
Disease-Free Survival
Biomarkers
Regression Analysis

Keywords

  • Biomarker
  • Pancreatic cancer
  • Prognosis
  • Serum albumin
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prognostic significance of the postoperative level and recovery rate of serum albumin in patients with curatively resected pancreatic ductal adenocarcinoma. / Nakano, Yutaka; Kitago, Minoru; Shinoda, Masahiro; Yagi, Hiroshi; Abe, Yuta; Takano, Kiminori; Oshima, Go; Takeuch, Ayano; Endo, Yutaka; Kitagawa, Yuko.

In: Molecular and Clinical Oncology, Vol. 11, No. 3, 01.09.2019, p. 270-278.

Research output: Contribution to journalArticle

@article{94bfe17109ca4807a7d5e1cc052500ee,
title = "Prognostic significance of the postoperative level and recovery rate of serum albumin in patients with curatively resected pancreatic ductal adenocarcinoma",
abstract = "The aim of the present study was to investigate the clinicopathological features and prognostic factors associated with pre- and postoperative serum albumin levels in patients with curatively resected pancreatic ductal adenocarcinoma (PDAC). To achieve this, the data of patients who underwent pancreatectomy for PDAC between January 1995 and March 2016 were retrospectively reviewed, and the pre- and postoperative serum albumin levels at postoperative months (POMs) 3, 6, and 12 were evaluated. The serum albumin recovery rate was also investigated. A total of 196 patients were enrolled in the present study. In the multivariate Cox regression analysis, lymph node metastasis [hazard ratio (HR): 1.65; P=0.022], serum albumin level at POM 12 (≥3.9 g/dl; HR: 0.60; P=0.017), and serum albumin recovery rate at POM 12 (≥1.00; HR: 0.60; P=0.017) were independent prognostic factors for disease-free survival. Lymph node metastasis (HR: 1.79; P=0.013) and serum albumin level at POM 12 (≥3.9 g/dl) (HR: 0.60; P=0.033) were independent prognostic factors for overall survival. These results indicated that the postoperative level and recovery rate of serum albumin are potential biomarkers for predicting the prognosis of patients with curatively resected PDAC. However, further studies are required in order to investigate the survival benefit of increasing postoperative serum albumin levels in these patients.",
keywords = "Biomarker, Pancreatic cancer, Prognosis, Serum albumin, Survival",
author = "Yutaka Nakano and Minoru Kitago and Masahiro Shinoda and Hiroshi Yagi and Yuta Abe and Kiminori Takano and Go Oshima and Ayano Takeuch and Yutaka Endo and Yuko Kitagawa",
year = "2019",
month = "9",
day = "1",
doi = "10.3892/mco.2019.1883",
language = "English",
volume = "11",
pages = "270--278",
journal = "Molecular and Clinical Oncology",
issn = "2049-9450",
number = "3",

}

TY - JOUR

T1 - Prognostic significance of the postoperative level and recovery rate of serum albumin in patients with curatively resected pancreatic ductal adenocarcinoma

AU - Nakano, Yutaka

AU - Kitago, Minoru

AU - Shinoda, Masahiro

AU - Yagi, Hiroshi

AU - Abe, Yuta

AU - Takano, Kiminori

AU - Oshima, Go

AU - Takeuch, Ayano

AU - Endo, Yutaka

AU - Kitagawa, Yuko

PY - 2019/9/1

Y1 - 2019/9/1

N2 - The aim of the present study was to investigate the clinicopathological features and prognostic factors associated with pre- and postoperative serum albumin levels in patients with curatively resected pancreatic ductal adenocarcinoma (PDAC). To achieve this, the data of patients who underwent pancreatectomy for PDAC between January 1995 and March 2016 were retrospectively reviewed, and the pre- and postoperative serum albumin levels at postoperative months (POMs) 3, 6, and 12 were evaluated. The serum albumin recovery rate was also investigated. A total of 196 patients were enrolled in the present study. In the multivariate Cox regression analysis, lymph node metastasis [hazard ratio (HR): 1.65; P=0.022], serum albumin level at POM 12 (≥3.9 g/dl; HR: 0.60; P=0.017), and serum albumin recovery rate at POM 12 (≥1.00; HR: 0.60; P=0.017) were independent prognostic factors for disease-free survival. Lymph node metastasis (HR: 1.79; P=0.013) and serum albumin level at POM 12 (≥3.9 g/dl) (HR: 0.60; P=0.033) were independent prognostic factors for overall survival. These results indicated that the postoperative level and recovery rate of serum albumin are potential biomarkers for predicting the prognosis of patients with curatively resected PDAC. However, further studies are required in order to investigate the survival benefit of increasing postoperative serum albumin levels in these patients.

AB - The aim of the present study was to investigate the clinicopathological features and prognostic factors associated with pre- and postoperative serum albumin levels in patients with curatively resected pancreatic ductal adenocarcinoma (PDAC). To achieve this, the data of patients who underwent pancreatectomy for PDAC between January 1995 and March 2016 were retrospectively reviewed, and the pre- and postoperative serum albumin levels at postoperative months (POMs) 3, 6, and 12 were evaluated. The serum albumin recovery rate was also investigated. A total of 196 patients were enrolled in the present study. In the multivariate Cox regression analysis, lymph node metastasis [hazard ratio (HR): 1.65; P=0.022], serum albumin level at POM 12 (≥3.9 g/dl; HR: 0.60; P=0.017), and serum albumin recovery rate at POM 12 (≥1.00; HR: 0.60; P=0.017) were independent prognostic factors for disease-free survival. Lymph node metastasis (HR: 1.79; P=0.013) and serum albumin level at POM 12 (≥3.9 g/dl) (HR: 0.60; P=0.033) were independent prognostic factors for overall survival. These results indicated that the postoperative level and recovery rate of serum albumin are potential biomarkers for predicting the prognosis of patients with curatively resected PDAC. However, further studies are required in order to investigate the survival benefit of increasing postoperative serum albumin levels in these patients.

KW - Biomarker

KW - Pancreatic cancer

KW - Prognosis

KW - Serum albumin

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85071293654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071293654&partnerID=8YFLogxK

U2 - 10.3892/mco.2019.1883

DO - 10.3892/mco.2019.1883

M3 - Article

VL - 11

SP - 270

EP - 278

JO - Molecular and Clinical Oncology

JF - Molecular and Clinical Oncology

SN - 2049-9450

IS - 3

ER -